首页> 外文期刊>BMC Immunology >Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia
【24h】

Impact of hepatitis C virus co-infection on HIV patients before and after highly active antiretroviral therapy: an immunological and clinical chemistry observation, Addis Ababa, Ethiopia

机译:高效抗逆转录病毒治疗前后丙型肝炎病毒共感染对HIV患者的影响:免疫学和临床化学观察,埃塞俄比亚亚的斯亚贝巴

获取原文
       

摘要

Background Hepatitis C virus (HCV) is an RNA virus which has been known to cause acute and chronic necro-inflammatory disease of the liver. It is the leading cause of end-stage liver disease and hepatocellular carcinoma. HIV is known to have a negative impact on the natural disease outcome and immune response of HCV infection, whereas the reverse remains unclear. We evaluated the impact of HCV co-infection on recovery of CD4+ and CD8+ T-cells and liver enzyme levels before and after initiation of highly active antiretroviral therapy (HAART) in HIV/HCV co-infected patients. Methods A hospital-based, observational, prospective cohort study design was used for this study. Pre-antiretroviral treatment (Pre-ART) and under HAART HIV mono-infected and HCV/HIV co-infected individuals who are under regular follow-up were recruited for this study. 387 blood samples were collected from volunteer, known HIV positive Ethiopian patients and screened for HCV. Twenty five HCV/HIV co-infected patients were prospectively followed for four years. CD4+ and CD8+ T-cells and liver enzyme levels were determined annually for each of the participant. Results The prevalence of HCV/HIV co-infection in this study was 6.5%. Both HCV/HIV co-infected and HIV mono-infected under HAART groups showed CD4+ recovery (343 Vs 426; P? OR?=?4.97, 95% CI?=?2.41 to 10.27) respectively; but, the recovery rate was higher in mono-infected (80 Vs 426) than co-infected group (148 Vs 343). The recovery and/or decline pattern of CD8+ T-cells was the same with that of CD4+. In 75% of co-infected groups, the mean alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels were above the upper limit of normal reference range. Analyses restricted to individuals who initiated HAART and pre-ART showed similar results. Conclusion We found that CD4+ T-cell recovery was negatively affected by the presence of ongoing HCV replication in under HAART co-infected individuals and fast decline of CD4+ T-cells in pre-ART patients. It was also associated with increased ALT and AST enzyme levels in both HAART initiated and treatment na?ve co-infected patients.
机译:背景技术丙型肝炎病毒(HCV)是一种RNA病毒,已知会引起肝脏的急性和慢性坏死性炎症。它是终末期肝病和肝细胞癌的主要原因。众所周知,HIV对自然疾病的结局和HCV感染的免疫反应具有负面影响,但目前还不清楚。我们评估了高活性抗逆转录病毒治疗(HAART)前后HCV合并感染对CD4 + 和CD8 + T细胞和肝酶水平恢复的影响。 HIV / HCV合并感染的患者。方法采用以医院为基础的观察性前瞻性队列研究设计。招募了接受抗逆转录病毒治疗前(Pre-ART)以及在HAART之下接受定期随访的HIV感染者和HCV / HIV合并感染者。从志愿者,已知的HIV阳性埃塞俄比亚患者中收集了387份血液样本,并进行了HCV筛查。前瞻性随访了25名HCV / HIV合并感染患者,为期4年。每年确定每位参与者的CD4 + 和CD8 + T细胞和肝酶水平。结果本研究中HCV / HIV合并感染的发生率为6.5%。在HAART组中,HCV / HIV合并感染和HIV单一感染均显示CD4 + 恢复(分别为343 Vs 426; P?OR?=?4.97,95%CI?=?2.41至10.27)。 ;但是,单感染(80 Vs 426)的恢复率高于联合感染组(148 Vs 343)。 CD8 + T细胞的恢复和/或下降模式与CD4 + 相同。在75%的合并感染组中,丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)的平均水平高于正常参考范围的上限。仅限于发起HAART和pre-ART的个人进行的分析显示了相似的结果。结论我们发现,在HAART合并感染的个体中,正在进行的HCV复制以及CD4 + T细胞的快速下降对CD4 + T细胞的恢复有负面影响。在ART前患者中。在HAART起始和未经治疗的合并感染患者中,它也与ALT和AST酶水平升高有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号